Management of acute pulmonary embolism: A contemporary, risk-tailored approach

Hellenic Journal of Cardiology

Volumn 51, Issue 5, 2010, Pages 437-450

  Chalikias, Georgios K ^a   Tziakas, Dimitrios N ^a   Stakos, Dimitrios A ^a   Konstantinides, Stavros V ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Anticoagulation; Heparin; Pulmonary embolism; Thrombolysis

Indexed keywords

ALTEPLASE; ENOXAPARIN; FATTY ACID BINDING PROTEIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NATRIURETIC FACTOR; STREPTOKINASE; TINZAPARIN; TROPONIN I; TROPONIN T; UROKINASE;

ACUTE PULMONARY EMBOLISM; ANTICOAGULANT THERAPY; CARDIOVASCULAR RISK; CONTINUOUS INFUSION; DEEP VEIN THROMBOSIS; DISEASE MARKER; DISEASE SEVERITY; EMBOLECTOMY; FIBRINOLYTIC THERAPY; HEART DISEASE; HEART MUSCLE INJURY; HEART RIGHT VENTRICLE FUNCTION; HIGH RISK PATIENT; HUMAN; LOADING DRUG DOSE; LUNG EMBOLECTOMY; LUNG EMBOLISM; LUNG HEMODYNAMICS; PRIMARY PREVENTION; REVIEW; RISK ASSESSMENT; SECONDARY PREVENTION; VENA CAVA FILTER;

ANTICOAGULANTS; EMBOLECTOMY; FATTY ACID-BINDING PROTEINS; HEMODYNAMICS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PULMONARY EMBOLISM; RECURRENCE; RISK ASSESSMENT; THROMBOLYTIC THERAPY; TOMOGRAPHY, X-RAY COMPUTED; TROPONIN; VENA CAVA FILTERS; VENOUS THROMBOEMBOLISM; VENTRICULAR DYSFUNCTION, RIGHT;

EID: 78049332893     PISSN: 10117970     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (110)

1. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 1998; 158: 585-593.
2. Anderson FA, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med. 1991; 151: 933-938.
3. White RH. The epidemiology of venous thromboembolism. Circulation. 2003; 107: I4-8.
4. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet. 1999; 353: 1386-1389.
5. Kasper W, Konstantinides S, Geibel A, et al. Management strategies and determinants of outcome in acute major pulmonary embolism: results of a multicenter registry. J Am Coll Cardiol. 1997; 30: 1165-1171.
6. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Research Committee of the British Thoracic Society. Lancet. 1992; 340: 873-876.
7. Carson JL, Kelley MA, Duff A, et al. The clinical course of pulmonary embolism. N Engl J Med. 1992; 326: 1240-1245.
8. Aujesky D, Jiménez D, Mor MK, Geng M, Fine MJ, Ibrahim SA. Weekend versus weekday admission and mortality after acute pulmonary embolism. Circulation. 2009; 119: 962-968.
9. Laporte S, Mismetti P, Decousus H, et al; RIETE Investigators. Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism: findings from the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) Registry. Circulation. 2008; 117: 1711-1716.
10. United States Department of Health and Human Services. The Surgeon General's Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism, 2008.
11. Cohen AT, Agnelli G, Anderson FA, et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost. 2007; 98: 756-764.
12. Cohen AT, Edmondson RA, Phillips MJ, Ward VP, Kakkar VV. The changing pattern of venous thromboembolic disease. Haemostasis. 1996; 26: 65-71.
13. Lindblad B, Sternby NH, Bergqvist D. Incidence of venous thromboembolism verified by necropsy over 30 years. BMJ. 1991;302:709-711.
14. Torbicki A, Perrier A, Konstantinides S, et al. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J. 2008; 29: 2276-2315.
15. Kasper W, Konstantinides S, Geibel A, Tiede N, Krause T, Just H. Prognostic significance of right ventricular afterload stress detected by echocardiography in patients with clinically suspected pulmonary embolism. Heart. 1997; 77: 346-349.
16. Konstantinides S. Pulmonary embolism: impact of right ventricular dysfunction. Curr Opin Cardiol. 2005; 20: 496-501. (Pubitemid 41565332)
17. McIntyre KM, Sasahara AA. Determinants of right ventricular function and hemodynamics after pulmonary embolism. Chest. 1974; 65: 534-543.
18. Miller RL, Das S, Anandarangam T, et al. Association between right ventricular function and perfusion abnormalities in hemodynamically stable patients with acute pulmonary embolism. Chest. 1998; 113: 665-670. (Pubitemid 28130939)
19. Greyson C, Xu Y, Cohen J, Schwartz GG. Right ventricular dysfunction persists following brief right ventricular pressure overload. Cardiovasc Res. 1997; 34: 281-288. (Pubitemid 27241572)
20. Schmitto JD, Doerge H, Post H, et al. Progressive right ventricular failure is not explained by myocardial ischemia in a pig model of right ventricular pressure overload. Eur J Cardiothorac Surg. 2009; 35: 229-234.
21. Chung T, Connor D, Joseph J, et al. Platelet activation in acute pulmonary embolism. J Thromb Haemost. 2007; 5: 918-924.
22. Smulders YM. Pathophysiology and treatment of haemodynamic instability in acute pulmonary embolism: the pivotal role of pulmonary vasoconstriction. Cardiovasc Res. 2000; 48: 23-33.
23. Konstantinides S. Clinical practice. Acute pulmonary embolism. N Engl J Med. 2008; 359: 2804-2813.
24. Kucher N, Rossi E, De Rosa M, Goldhaber SZ. Massive pulmonary embolism. Circulation. 2006; 113: 577-582.
25. Grifoni S, Olivotto I, Cecchini P, et al. Short-term clinical outcome of patients with acute pulmonary embolism, normal blood pressure, and echocardiographic right ventricular dysfunction. Circulation. 2000; 101: 2817-2822.
26. Stein PD, Henry JW. Prevalence of acute pulmonary embolism among patients in a general hospital and at autopsy. Chest. 1995; 108: 978-981.
27. Kucher N, Goldhaber SZ. Management of massive pulmonary embolism. Circulation. 2005; 112: e28-32.
28. Ribeiro A, Lindmarker P, Juhlin-Dannfelt A, Johnsson H, Jorfeldt L. Echocardiography Doppler in pulmonary embolism: right ventricular dysfunction as a predictor of mortality rate. Am Heart J. 1997; 134: 479-487.
29. Goldhaber SZ, Haire WD, Feldstein ML, et al. Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion. Lancet. 1993; 341: 507-511.
30. Kucher N, Rossi E, De Rosa M, Goldhaber SZ. Prognostic role of echocardiography among patients with acute pulmonary embolism and a systolic arterial pressure of 90 mmHg or higher. Arch Intern Med. 2005; 165: 1777-1781.
31. ten Wolde M, Söhne M, Quak E, Mac Gillavry MR, Büller HR. Prognostic value of echocardiographically assessed right ventricular dysfunction in patients with pulmonary embolism. Arch Intern Med. 2004; 164: 1685-1689.
32. Kasper W, Geibel A, Tiede N, et al. Distinguishing between acute and subacute massive pulmonary embolism by conventional and Doppler echocardiography. Br Heart J. 1993; 70: 352-356.
33. Sanchez O, Trinquart L, Colombet I, et al. Prognostic value of right ventricular dysfunction in patients with haemodynamically stable pulmonary embolism: a systematic review. Eur Heart J. 2008; 29: 1569-1577.
34. Konstantinides S, Geibel A, Heusel G, Heinrich F, Kasper W. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med. 2002; 347: 1143-1150.
35. Binder L, Pieske B, Olschewski M, et al. N-terminal pro-brain natriuretic peptide or troponin testing followed by echocardiography for risk stratification of acute pulmonary embolism. Circulation. 2005; 112: 1573-1579.
36. Sanchez O, Trinquart L, Caille V, et al. Prognostic factors for pulmonary embolism: the prep study, a prospective multicenter cohort study. Am J Respir Crit Care Med. 2010; 181: 168-173.
37. Schoepf UJ, Kucher N, Kipfmueller F, Quiroz R, Costello P, Goldhaber SZ. Right ventricular enlargement on chest computed tomography: a predictor of early death in acute pulmonary embolism. Circulation. 2004; 110: 3276-3280. (Pubitemid 39525077)
38. van der Meer RW, Pattynama PM, van Strijen MJ, et al. Right ventricular dysfunction and pulmonary obstruction index at helical CT: prediction of clinical outcome during 3-month follow-up in patients with acute pulmonary embolism. Radiology. 2005; 235: 798-803.
39. Kucher N, Printzen G, Doernhoefer T, Windecker S, Meier B, Hess OM. Low pro-brain natriuretic peptide levels predict benign clinical outcome in acute pulmonary embolism. Circulation. 2003; 107: 1576-1578.
40. Kucher N, Printzen G, Goldhaber SZ. Prognostic role of brain natriuretic peptide in acute pulmonary embolism. Circulation. 2003; 107: 2545-2547.
41. Pruszczyk P, Kostrubiec M, Bochowicz A, et al. N-terminal pro-brain natriuretic peptide in patients with acute pulmonary embolism. Eur Respir J. 2003; 22: 649-653.
42. ten Wolde M, Tulevski II, Mulder JWM, et al. Brain natriuretic peptide as a predictor of adverse outcome in patients with pulmonary embolism. Circulation. 2003; 107: 2082-2084.
43. Kucher N, Goldhaber SZ. Cardiac biomarkers for risk stratification of patients with acute pulmonary embolism. Circulation. 2003; 108: 2191-2194. (Pubitemid 37363033)
44. Giannitsis E, Katus HA. Risk stratification in pulmonary embolism based on biomarkers and echocardiography. Circulation. 2005; 112: 1520-1521.
45. Klok FA, Mos ICM, Huisman MV. Brain-type natriuretic peptide levels in the prediction of adverse outcome in patients with pulmonary embolism: a systematic review and meta-analysis. Am J Respir Crit Care Med. 2008; 178: 425-430.
46. Korff S, Katus HA, Giannitsis E. Differential diagnosis of elevated troponins. Heart. 2006; 92: 987-993.
47. Becattini C, Vedovati MC, Agnelli G. Prognostic value of troponins in acute pulmonary embolism: a meta-analysis. Circulation. 2007; 116: 427-433.
48. Moores L, Aujesky D, Jiménez D, et al. Pulmonary embolism severity index and troponin testing for the selection of lowrisk patients with acute symptomatic pulmonary embolism. J Thromb Haemost. 2010; 8: 517-522.
49. Jiménez D, Uresandi F, Otero R, et al. Troponin-based risk stratification of patients with acute nonmassive pulmonary embolism: systematic review and metaanalysis. Chest. 2009; 136: 974-982.
50. Lankeit M, Konstantinides S. Tenecteplase can be given to patients with intermediate-risk pulmonary embolism - But should it? Thromb Res 2009 Nov 5. [Epub ahead of print]
51. Storch J, Thumser AE. The fatty acid transport function of fatty acid-binding proteins. Biochim Biophys Acta. 2000; 1486: 28-44.
52. Alhadi HA, Fox KAA. Do we need additional markers of myocyte necrosis: the potential value of heart fatty-acid-binding protein. QJM. 2004; 97: 187-198.
53. Pelsers MMAL, Hermens WT, Glatz JFC. Fatty acid-binding proteins as plasma markers of tissue injury. Clin Chim Acta. 2005; 352: 15-35.
54. Puls M, Dellas C, Lankeit M, et al. Heart-type fatty acid-binding protein permits early risk stratification of pulmonary embolism. Eur Heart J. 2007; 28: 224-229.
55. Kaczyñska A, Pelsers MMAL, Bochowicz A, Kostrubiec M, Glatz JFC, Pruszczyk P. Plasma heart-type fatty acid binding protein is superior to troponin and myoglobin for rapid risk stratification in acute pulmonary embolism. Clin Chim Acta. 2006; 371: 117-123. (Pubitemid 44162903)
56. Dellas C, Puls M, Lankeit M, et al. Elevated heart-type fatty acid-binding protein levels on admission predict an adverse outcome in normotensive patients with acute pulmonary embolism. J Am Coll Cardiol. 2010; 55: 2150-2157.
57. Kempf T, Eden M, Strelau J, et al. The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ Res. 2006; 98: 351-360. (Pubitemid 43755331)
58. Xu J, Kimball TR, Lorenz JN, et al. GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation. Circ Res. 2006; 98: 342-350. (Pubitemid 43755330)
59. Lankeit M, Kempf T, Dellas C, et al. Growth differentiation factor-15 for prognostic assessment of patients with acute pulmonary embolism. Am J Respir Crit Care Med. 2008; 177: 1018-1025. (Pubitemid 351717597)
60. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet. 1999; 353: 1386-1389. (Pubitemid 29192409)
61. Aujesky D, Roy P-M, Le Manach CP, et al. Validation of a model to predict adverse outcomes in patients with pulmonary embolism. Eur Heart J. 2006; 27: 476-481.
62. Aujesky D, Obrosky DS, Stone RA, et al. Derivation and validation of a prognostic model for pulmonary embolism. Am J Respir Crit Care Med. 2005; 172: 1041-1046.
63. Jiménez D, Yusen RD, Otero R, et al. Prognostic models for selecting patients with acute pulmonary embolism for initial outpatient therapy. Chest. 2007; 132: 24-30. (Pubitemid 47068199)
64. Aujesky D, Roy P-M, Le Manach CP, et al. Validation of a model to predict adverse outcomes in patients with pulmonary embolism. Eur Heart J. 2006; 27: 476-481. (Pubitemid 43209175)
65. Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivas S. The weight-based heparin dosing nomogram compared with a "standard care" nomogram. A randomized controlled trial. Ann Intern Med. 1993; 119: 874-881.
66. Quinlan DJ, McQuillan A, Eikelboom JW. Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials. Ann Intern Med. 2004; 140: 175-183.
67. Arepally GM, Ortel TL. Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med. 2006; 355: 809-817.
68. Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133: 340S-380S.
69. Wan S, Quinlan DJ, Agnelli G, Eikelboom JW. Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials. Circulation. 2004; 110: 744-749.
70. Meneveau N, Séronde M-F, Blonde M-C, et al. Management of unsuccessful thrombolysis in acute massive pulmonary embolism. Chest. 2006; 129: 1043-1050.
71. Daniels LB, Parker JA, Patel SR, Grodstein F, Goldhaber SZ. Relation of duration of symptoms with response to thrombolytic therapy in pulmonary embolism. Am J Cardiol. 1997; 80: 184-188.
72. Konstantinides S, Tiede N, Geibel A, Olschewski M, Just H, Kasper W. Comparison of alteplase versus heparin for resolution of major pulmonary embolism. Am J Cardiol. 1998; 82: 966-970. (Pubitemid 28480783)
73. Dalen JE, Alpert JS, Hirsh J. Thrombolytic therapy for pulmonary embolism: is it effective? Is it safe? When is it indicated? Arch Intern Med. 1997; 157: 2550-2556.
74. Kanter DS, Mikkola KM, Patel SR, Parker JA, Goldhaber SZ. Thrombolytic therapy for pulmonary embolism. Frequency of intracranial hemorrhage and associated risk factors. Chest. 1997; 111: 1241-1245.
75. Tebbe U, Graf A, Kamke W, et al. Hemodynamic effects of double bolus reteplase versus alteplase infusion in massive pulmonary embolism. Am Heart J. 1999; 138: 39-44.
76. Becattini C, Agnelli G, Salvi A, et al. Bolus tenecteplase for right ventricle dysfunction in hemodynamically stable patients with pulmonary embolism. Thromb Res. 2010; 125: e82-86.
77. Leacche M, Unic D, Goldhaber SZ, et al. Modern surgical treatment of massive pulmonary embolism: results in 47 consecutive patients after rapid diagnosis and aggressive surgical approach. J Thorac Cardiovasc Surg. 2005; 129: 1018-1023.
78. Pacouret G, Alison D, Pottier JM, Bertrand P, Charbonnier B. Free-floating thrombus and embolic risk in patients with angiographically confirmed proximal deep venous thrombosis. A prospective study. Arch Intern Med. 1997; 157: 305-308.
79. Douketis JD, Kearon C, Bates S, Duku EK, Ginsberg JS. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA. 1998; 279: 458-462.
80. Decousus H, Leizorovicz A, Parent F, et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med. 1998; 338: 409-415.
81. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133: 454S-545S.
82. Kurzyna M, Torbicki A, Pruszczyk P, et al. Disturbed right ventricular ejection pattern as a new Doppler echocardiographic sign of acute pulmonary embolism. Am J Cardiol. 2002; 90: 507-511.
83. Weg JG, Froehlich JB. Ultrasonography of leg veins in patients suspected of having pulmonary embolism. Ann Intern Med. 1998; 128: 243.
84. Pruszczyk P, Torbicki A, Kuch-Wocial A, Szulc M, Pacho R. Diagnostic value of transoesophageal echocardiography in suspected haemodynamically significant pulmonary embolism. Heart. 2001; 85: 628-634.
85. Torbicki A, Galié N, Covezzoli A, Rossi E, De Rosa M, Goldhaber SZ. Right heart thrombi in pulmonary embolism: results from the International Cooperative Pulmonary Embolism Registry. J Am Coll Cardiol. 2003; 41: 2245-2251.
86. Wells PS, Anderson DR, Rodger M, et al. Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost. 2000; 83: 416-420.
87. Value of the ventilation/perfusion scan in acute pulmonary embolism. Results of the prospective investigation of pulmonary embolism diagnosis (PIOPED). The PIOPED Investigators. JAMA. 1990; 263: 2753-2759.
88. Stein PD, Fowler SE, Goodman LR, et al. Multidetector computed tomography for acute pulmonary embolism. N Engl J Med. 2006; 354: 2317-2327.
89. Wicki J, Perrier A, Perneger TV, Bounameaux H, Junod AF. Predicting adverse outcome in patients with acute pulmonary embolism: a risk score. Thromb Haemost. 2000; 84: 548-552.
90. Wells PS, Ginsberg JS, Anderson DR, et al. Use of a clinical model for safe management of patients with suspected pulmonary embolism. Ann Intern Med. 1998; 129: 997-1005.
91. Le Gal G, Righini M, Roy P-M, et al. Prediction of pulmonary embolism in the emergency department: the revised Geneva score. Ann Intern Med. 2006; 144: 165-171.
92. Söhne M, Kamphuisen PW, van Mierlo PJWB, Büller HR. Diagnostic strategy using a modified clinical decision rule and D-dimer test to rule out pulmonary embolism in elderly in- and outpatients. Thromb Haemost. 2005; 94: 206-210.
93. Gibson NS, Sohne M, Kruip MJHA, et al. Further validation and simplification of the Wells clinical decision rule in pulmonary embolism. Thromb Haemost. 2008; 99: 229-234.
94. Stein PD, Fowler SE, Goodman LR, et al. Multidetector computed tomography for acute pulmonary embolism. N Engl J Med. 2006; 354: 2317-2327.
95. Stein PD, Woodard PK, Weg JG, et al. Diagnostic pathways in acute pulmonary embolism: recommendations of the PIOPED II Investigators. Radiology. 2007; 242: 15-21.
96. Anderson DR, Kahn SR, Rodger MA, et al. Computed tomographic pulmonary angiography vs ventilation-perfusion lung scanning in patients with suspected pulmonary embolism: a randomized controlled trial. JAMA. 2007; 298: 2743-2753.
97. Davies CWH, Wimperis J, Green ES, et al. Early discharge of patients with pulmonary embolism: a two-phase observational study. Eur Respir J. 2007; 30: 708-714.
98. Otero R, Uresandi F, Jimenez D, et al. Home treatment in pulmonary embolism. Thromb Res. 2010; 126: e1-5.
99. Jiménez D, Yusen RD. Prognostic models for selecting patients with acute pulmonary embolism for initial outpatient therapy. Curr Opin Pulm Med. 2008; 14: 414-421.
100. Kearon C. Natural history of venous thromboembolism. Circulation. 2003; 107: I22-30.
101. Murin S, Romano PS, White RH. Comparison of outcomes after hospitalization for deep venous thrombosis or pulmonary embolism. Thromb Haemost. 2002; 88: 407-414.
102. Hansson PO, Sörbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med. 2000; 160: 769-774.
103. Heit JA, Mohr DN, Silverstein MD, Petterson TM, O'Fallon WM, Melton LJ. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based co hort study. Arch Intern Med. 2000; 160: 761-768.
104. Prandoni P, Lensing AW, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med. 1996; 125: 1-7.
105. Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism [see comments] [published erratum appears in N Engl J Med. 1999; 341: 298]. N Engl J Med. 1999; 340: 901-907.
106. Douketis JD, Gu CS, Schulman S, Ghirarduzzi A, Pengo V, Prandoni P. The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism. Ann Intern Med. 2007; 147: 766-774.
107. Agnelli G, Prandoni P, Becattini C, et al. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med. 2003; 139: 19-25.
108. Linkins L-A, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med. 2003; 139: 893-900.
109. Palareti G, Cosmi B, Legnani C, et al. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med. 2006; 355: 1780-1789.
110. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009; 361: 2342-2352.